Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDPML followed by MA for newly diagnosed aggressive T-cell lymphoma
ChiCTR-ONC-12002055Phase 4Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gemcitabine, cisplatin, dexamethasone, pegaspargase, methotrexate and 1 more in aggressive T-cell lymphoma (PTCL), sponsored by Peking Union Medical College Hospital. Primary endpoints: Overall response rate and Time to progression. Started Feb 2012; status: completed.
02
Drugs
gemcitabinecisplatindexamethasonepegaspargasemethotrexate
03
Conditions
aggressive T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR-ONC-12002055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002055.